0 CHECKOUT

Intranasal Drug Delivery - Global Strategic Business Report

  • ID: 516888
  • May 2016
  • Region: Global
  • 212 Pages
  • Global Industry Analysts, Inc
1 of 3

This report analyzes the US market for Intranasal Drug Delivery in US$ Million by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for this market. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 59 companies including many key and niche players such as -

Aegis Therapeutics LLC
AptarGroup, Inc.
AstraZeneca Plc
Becton Dickinson and Company
GlaxoSmithKline Plc

Note: Product cover images may vary from those shown
2 of 3

INTRANASAL DRUG DELIVERY

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definition and Scope of Study

II. A US MARKET REPORT

1. INDUSTRY OVERVIEW
Prelude
Intranasal Cavity: An Attractive Drug Delivery Route to Cross the Blood Brain Barrier
Bioavailability: An Important Facet of Intranasal Drug Delivery
Chemical Modification
Transient Modification & Limited Enzymatic Activity
Bioavailability of Large Molecules
Bio-Adhesive Polymers: Useful in Increasing Drug Absorption
Outlook
Nasal Drug Delivery Devices & Equipment
Preservative Free Systems (PFS)
Traditional Vs. Advanced Intranasal Drug Formulation Types
Type of Nasal Delivery Vehicles with Select Therapeutic Agents and Area of Application

2. MARKET DRIVERS, TRENDS & ISSUES
Burgeoning Geriatric Populace Spurs Growing Demand for Intranasal Drug Therapies
Table 1: Global Population Estimates (in Billion): 2000-2050P (includes corresponding Graph/Chart)
Table 2: Aging (65+) Demographics as a Percentage of Total Population for Major Countries: 2000, 2011, and 2020 (includes corresponding Graph/Chart)
Table 3: Global Aging Population (in Thousands) by Age Group: 1975, 2000, 2025, and 2050 (includes corresponding Graph/Chart)
Table 4: Global Population Statistics for the 65+ Age Group (Male & Female) for Major Countries/Regions: 2013 (includes corresponding Graph/Chart)
Table 5: Global Life Expectancy at Age 60 and 80 Years: 2010-2015; 2020-2025; and 2045-2050 (includes corresponding Graph/Chart)
Table 6: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart)
Table 7: US Geriatric Population by Age Group (2000, 2010, 2020, 2030 & 2050): Percentage Share of US Population of Senior Citizens of Age Group 65-75 Years, 75- 84 Years, and 85 Years and Above (includes corresponding Graph/Chart)
Nasal Drug Delivery Offers New Opportunities for Drug Developers as Patent Cliffs Usher in Dusk of Blockbuster Era
Table 8: Top Nasal Inhalers, Sprays, and Drops Brands in the US (2015): Percentage Share Breakdown of Dollar Sales for Afrin, Afrin No Drip, Arm & Hammer Simply Saline, Neilmed Sinus Rinse, Vicks Sinex, Zicam, Private Labels, and Others (includes corresponding Graph/Chart)
Pharmaceutical and Medical Device Companies Vying to Develop New Intranasal Therapeutics for Allergic Rhinitis Patients
Table 9: Prevalence Percentage of COPD, Asthma, and Allergic Rhinitis for Select Countries: 2016E (includes corresponding Graph/Chart)
Table 10: The US Allergic Rhinitis Patient Population by Disease Severity (2015): Percentage Breakdown of Patient Pool for Mild Intermittent, Mild Persistent, Moderate-severe Intermittent, and Moderate-severe Persistent (includes corresponding Graph/Chart)
The US-FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
The US FDA-Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
Table 11: Global Respiratory Drugs Market by Category (2015 & 2020): Percentage Breakdown of Dollar Values for COPD Therapies, Inhaled Steroids, Long Acting Beta Agonists, Nasal Steroids, and Others (includes corresponding Graph/Chart)
US FDA Approved Intranasal Corticosteroids (INAC) and Intranasal Antihistamines (INAH) for Treating Allergic Rhinitis
US FDA Approved Nasal Spray Medication Types (excluding INAC & INAH) for Allergic Rhinitis Treatment
Intranasal Corticosteroids
A Potential Treatment for Debilitating Chronic Rhinosinusitis Disease
Select Intranasal Corticosteroid Brands for Adult and Pediatric Usage
Select Intranasal Corticosteroids in Pipeline Indicated for Treating Allergic Rhinitis: 2015
Self-Administration of Drugs Brings Intranasal Drug Delivery into the Spotlight
Innovation in Drug Delivery: A Talisman for Success
Active Pharmaceutical Ingredients Used in Formulations for Nasal Drug Delivery with Related Indications
Controlled Release Technology Is the Buzz Word
Target-Specific Delivery Devices: Of Critical Value
Safety and Cost: Primary Growth Drivers
Increasing R&D Unlocks New Therapeutic Areas for Nasal Drug Delivery
Intranasal Therapeutics Delivery
A High Potential Method for Treating CNS Diseases
Intranasal Insulin Delivery Offers Strong Clinical Significance
Intranasal Delivery of Anti-emetic Agent Metoclopramide Hydrochloride Validated by Study on Rodents
Intranasal Delivery of Peptide-Based Pharmaceuticals
Select Protein, Peptide & Non-Peptide Drugs Available as Nasal Spray Solutions in the Marketplace
Tight Junction Biology: A Key Speed Breaker in Commercialization
RNA Interference (RNAi): A Tool to Manipulate Tight Junctions
Research Studies Authenticate Benefits of Bi-Directional Nasal Drug Delivery
Growing Interest for Preservative-free Nasal Spray Formulations
Multi-Dose Containers Developed to Offer Resistance against Microbial Contamination

3. RECENT RESEARCH & DEVELOPMENT INITIATIVES
Intranasal Administration of ATX-LIPO for Brain Targeting
A Promising Therapy for ADHD
Noteworthy Registered and Published Clinical Trials on Intranasal Psychotropics
Focused Ultrasound Leveraged to Enhance Intranasal Drug Delivery
Evoke Pharma Develops EVK-001 Intranasal Metoclopramide Delivery System for Treating Gastroparesis
Smart Polymers with Temperature, pH or Ionic Response in Nasal drug Delivery
Chitosan Thermosensitive Biogels Evaluated for Intranasal Delivery of CNS Drugs
Select Nasal Drug Absorption Enhancers and Related Mechanisms
Dendrimers to Enhance Water-solubility of Antipsychotic Drugs for Intranasal Administration
Naloxone Hydrochloride Nasal Sprays Provides a Powerful Alternative for Opioid Overdose Medications
OptiNose ONZETRA Xsail (AVP-825)
An Innovative Breath- Powered Intranasal Delivery System for Migraine Treatment
Clinical Study Demonstrates Faster Antidepression Effects of Intranasal Ketamine
Intranasal Aerosol Dose of PH94B Investigated for Treating Social Anxiety Disorder (SAD)

4. TECHNOLOGY OVERVIEW
Intranasal Drug Delivery: A Descriptive Exposition
Nasal Physiology
Challenges Involved In Formulating Nasal Drugs
The Importance of Bioadhesion
Overview of the Traditional Drug Administration Routes, Molecular Weight Capabilities, and Dosage Range
Intranasal Drugs
Prescription (Rx) and Over-the-Counter (OTC)
Differences between Systemic Delivery and Local Effects
Nasal Powders Vs. Sprays
Nasal Drug Delivery Devices
Types of Drug Delivery Devices
Droppers
Sprays
Aerosol Containers/Inhalers
Pumps
Nasal Aspirator
Intranasal Drug Delivery Vis-à-vis Other Delivery Techniques
Limitations of Intranasal Drug Delivery
Allergy
Definition
Symptoms
Allergic Rhinitis
Nasal Allergies

5. NASAL DRUGS: AN OVERVIEW
Nasal Drugs for Allergies
Corticosteroid Nasal Sprays
Flonase
Patanase
Beconase
Other Nasal Corticosteroid Drugs
Antihistamine Nasal Sprays
Astelin Nasal Spray
Otrivin Nasal Spray
Livostin Nasal Spray
Other Nasal Antihistamine Drugs
Select Brands of Allergy Relievers
Nasal Drugs for Postmenopausal Osteoporosis
Calcitonin-Salmon Nasal Spray
Miacalcin Nasal Spray
Fortical® Nasal Spray
Intranasal Pain Management Drugs
Stadol Nasal Spray
Imitrex
Migranal
Zolmitriptan Nasal Spray
Intranasal Analgesics for Treating Migraine
Intranasal Vaccination
Process of Intranasal Immunization
“LAIV” Nasal Spray Flu Vaccine
FluMist® Vaccine from MedImmune
Intranasal Drugs for Sexual Dysfunction
Nasal Spray for Treating Vitamin B12 Deficiency
Nasal Spray for Aiding Smoking Cessation

6. PRODUCT DEVELOPMENTS, APPROVALS & INTRODUCTIONS
Nemera Launches Advancia Multi-Dose Nasal Spray System
Adapt Pharma Launches Narcan Opioid Antagonist
Apotex Unveils Generic Version of Nasonex®
McNeil Consumer Healthcare Rolls Out OTC RHINOCORT®
Cipla Introduces Triamist Intranasal Corticosteroid
OptiNose Bags FDA Approval for ONZETRA™ Xsail™
Avanir’s Onzetra Secures FDA Approval
FDA Approves Lannett’s Sumatriptan Nasal Spray
Meda’s Dymista Bags Health Canada’s Approval
Endo Pharmaceuticals Announces Availability of NATESTO
AstraZenca Canada Unveils FluMist for Children
Perrigo Receives US FDA Approval for Generic Version of Sun Pharma's Kenalog
GSK Rolls Out OTC Version of Flonase Allergy Relief
Upsher-Smith Publishes Data from USL261 Phase 1 Trials
KemPharm Concludes KP201/APAP’s Human Abuse Liability Program
OptiNose Publishes Results of OPN 375’s Phase III Trial
NanoBio’s Genital Herpes Vaccine Proven Effective
Recro Pharma Releases Further Details of Dex-IN’s Phase II Clinical Trial
Evoke Announces Phase III Trials of EVK-001
FDA Accepts Filing of TARSA’s TBRIA
FDA Accepts Review of Pfizer’s ALO-02
Breckenridge Bags FDA Approval for Azelastine HCl Nasal Solution
ZOMIG® Gets FDA Approval
Sandoz Introduces Generic Version of Novartis NASONEX
Chattem Releases OTC NASACORT® ALLERGY 24HR NASAL SPRAY
FDA Approves QNASL Nasal Aerosol

7. RECENT INDUSTRY ACTIVITY
Egalet Inks Deal With Septodont for SPRIX® Promotion
Lilly Acquires Intranasal Glucagon Rights
UAE recalls Otrivin Nasal Spray Batches
Eli Lily Acquires Rights for Innovent’s Intranasal Glucagon
AstraZenca Commences Shipment of FluMist®
ProStrakan Concludes Archimedes Acquisition
Neurelis Inks Deal with Biotie Therapies
AntiOp Signs Pact for Developing Intranasal Naloxone
Depomed Acquires Lazanda® Nasal Spray
Novartis, Sandoz and Apotex Withdraws Synthetic Calcitonin Nasal Spray Products
Retrophin Inks Deal for Syntocinon Nasal Spray

8. FOCUS ON SELECT GLOBAL PLAYERS
Aegis Therapeutics LLC (USA)
AptarGroup, Inc. (USA)
AstraZeneca Plc. (UK)
MedImmune, Inc. (USA)
Becton Dickinson and Company (USA)
GlaxoSmithKline Plc. (UK)
Johnson & Johnson Inc. (USA)
Marina Biotech, Inc. (USA)
Merck & Co., Inc. (USA)
Nemera (France)
Novartis AG (Switzerland)
Optinose US Inc. (USA)
Pfizer, Inc. (USA)
Valeant Pharmaceuticals International Inc. (Canada)

9. US MARKET ANALYTICS
Table 12: The US Recent Past, Current & Future Analysis for Intranasal Drug Delivery Therapeutics by Therapeutic Area
Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)
Table 13: The US Historic Review for Intranasal Drug Delivery Therapeutics by Therapeutic Area
Allergic Infections, Analgesics, Osteoporosis, and Vaccinations Markets Independently Analyzed by Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)
Table 14: The US 14-Year Perspective for Intranasal Drug Delivery by Therapeutic Area
Percentage Breakdown of Values Sales for Allergic Infections, Analgesics, Osteoporosis, and Vaccinations for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE
Total Companies Profiled: 59 (including Divisions/Subsidiaries 79)
The United States (49)
Canada (6)
Japan (1)
Europe (18)
- France (2)
- Germany (4)
- The United Kingdom (7)
- Rest of Europe (5)
Asia-Pacific (Excluding Japan) (3)
Latin America (1)
Middle-East (1)

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Bayer AG
  • LEO Laboratories Ltd.
  • Grünenthal GmbH
  • Medtronic, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Pall Corporation